Teva falls short on Q3 profit, slashes 2017 estimates again

JERUSALEM (Reuters) - Debt-ridden Israeli drugmaker Teva Pharmaceutical Industries reported lower than expected profit in the third quarter and sharply lowered its 2017 estimates, as the company continues to be hurt by weak U.S. generic medicine sales.